Related Experiment Video
Updated: Jan 15, 2026

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
Remimazolam as a Novel Option for Procedural Sedation: A Narrative Review
Hubert Ziembicki1, Natalia Skrzypska2, Justyna Wróblewska2
1Clinical Department of Anesthesiology, Intensive Care, and Pain Management, University Clinical Hospital, Poznań, POL.
None:
Procedural sedation (PS) is a widely used practice designed to relieve anxiety, induce amnesia, and improve patient comfort during diagnostic and therapeutic procedures, particularly those that may cause discomfort. The choice of sedative agent plays a critical role in determining the depth of sedation, recovery time, and risk of adverse effects. Traditionally, midazolam, a benzodiazepine (BDZ), has been the agent of choice for PS due to its rapid onset and relatively short duration of action. However, midazolam's active metabolites can result in prolonged sedation, posing a risk of delayed recovery and increased complications. These drawbacks have sparked interest in the development of alternatives that offer a more favorable pharmacokinetic profile. Remimazolam, a novel ultra-short-acting BDZ, has emerged as a potential solution. Unlike midazolam, remimazolam has a rapid onset of action, a very short duration of effect, and no active metabolites, which significantly reduces the risk of prolonged sedation and enhances patient safety. Its unique pharmacological properties make it a promising candidate for PS, particularly in outpatient and short-duration procedures where rapid recovery is critical. This narrative review aims to evaluate the available literature on remimazolam as an agent for PS, with a focus on its pharmacology, safety profile, and clinical efficacy. A comprehensive literature search was conducted on PubMed and Google Scholar, focusing on studies published between 2015 and 2025. The review encompasses original research articles, clinical trials, systematic reviews, and preclinical studies that compare remimazolam with other sedatives, including midazolam, propofol, and ketamine. The findings from these studies were synthesized to highlight the advantages of remimazolam, including its rapid onset, short duration, and safety profile. Emphasis was placed on clinical studies assessing its efficacy in various procedural contexts, identifying gaps in the current evidence, and suggesting directions for future research.
More Related Videos
08:49Assessing Changes in Volatile General Anesthetic Sensitivity of Mice after Local or Systemic Pharmacological Intervention
Published on: October 16, 2013
14:52Recording Brain Electromagnetic Activity During the Administration of the Gaseous Anesthetic Agents Xenon and Nitrous Oxide in Healthy Volunteers
Published on: January 13, 2018
Related Concept Videos
Parenteral Anesthetics: Overview
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Inhalational Anesthetics: Overview
Stages of General Anesthesia